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ROB S. B. BEANLANDS,  MD,  FRCP(C) ,  ROBERT A. DEKEMP,  PHD, EEF  HARMSEN,  PHD, 
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Ottawa, Ontario, Canada 
Objectives. This study evaluated technetium-99m (Tc-99m) 
teboroxime kinetics in postischemic and partially necrotic myo- 
cardium with complete and low flow reperfusion using an isolated 
perfused rat heart model. 
Background. Technetium-99m teboroxime has been proposed 
for use in the early diagnosis of reperfusion after thrombolysis on 
the basis of models of myocardial necrosis with complete reper- 
fusion. Clinically, however, reperfusion is frequently incomplete, 
resulting in a mixture of necrotic, ischemic and postischemic 
tissue. 
Methods. Hearts were classified into five groups: group 1 (n = 
8, control); group 2 (n = 7, 30 min of no flow with complete 
reperfusion); group 3 (n = 12, 60 rain of no flow to induce partial 
necrosis, followed by complete reperfusion); group 4 (n = 8, 
continuous low flow without flow interruption); and group 5 (n = 
9, 60 min of no flow with low flow reperfusion). Buffer containing 
Tc-99m teboroxime was perfused for 15 min, followed by tracer- 
free buffer for 35 min, to evaluate uptake and clearance, respec- 
tively. 
Results. Uptake slopes for groups I to 5 were (mean -+ SD) 
3.0 -+ 0.7, 2.6 -+ 0.8, 2.1 -+ 0.5, 0.8 -+ 0.2 and 0.8 ± 0.3, respectively 
(p < 0.0005 for groups 1, 2 and 3 vs. groups 4 and 5, and p = 0.003 
for group 3 vs. groups 1 and 2). Clearance curves from groups 1 
to 3 were best fit by a biexponential function (p < 0.001); those 
from groups 4 and 5 were monoexponential. In groups 1, 2 and 3, 
the initial clearance rate constants (kl) (0.9 "4- 0.5 × 10-3; 1.0 -~ 
0.2 x 10-3; 1.1 ~- 0.5 x 10 -3 s -i, respectively) and the monoex- 
ponential rate constants (kmono) (2.0 -+ 0.3 X 10-4; 2.2 -- 0.4 × 
10-4; 2.1 -+ 0.2 × 10 -4 s -1, respectively) were significantly greater 
than those in groups 4 and 5 (0.9 -+ 0.5 x 10-4; 1.2 -+ 0.3 x 10 -4 
s -i, respectively, p _< 0.005). 
Conclusions. The uptake and initial clearance kinetics of 
Tc-99m teboroxime depend mainly on myocardial flow in this 
model. The presence of partial necrosis and postischemic injury 
has little effect on the initial clearance but leads to some reduction 
in uptake at normal flow rates. Evaluation of Tc-99m teboroxime 
kinetics may permit early noninvasive detection of inadequate 
reperfusion in acute myocardial infarction. 
(J Am Coil Cardio11996;28:487-94) 
In acute myocardial infarction, reestablishing adequate blood 
flow significantly reduces infarct size and morbidity and mor- 
tality (1). However, even with an aggressive front-loaded 
tissue-type plasminogen activator protocol, up to 46% of 
patients fail to achieve complete reperfusion (Thrombolysis in 
Myocardial Infarction trial flow grade 3) (2). In such patients, 
invasive therapies such as angioplasty may be indicated to 
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reestablish normal flow and to minimize the extent of left 
ventricular damage (3). Unfortunately, clinical variables and 
current noninvasive approaches have not been helpful in the 
early identification of such patients (4). Thus, invasive proce- 
dures, with their accompanying risks and costs, are necessary to 
establish the presence and degree of reperfusion in many 
patients. Clearly there is a need for a rapid, reliable and 
noninvasive technique to identify acute myocardial infarction 
in patients with inadequate reperfusion who require urgent 
invasive intervention. 
Recently, the kinetics of the new myocardial perfusion 
tracer Tc-99m teboroxime have been shown to correlate 
closely with myocardial blood flow over a wide range of flow 
rates (5-7). Noninvasive imaging of Tc-99m teboroxime kinet- 
ics could provide a method for the early diagnosis of reperfu- 
sion after thrombolysis. However, to establish the clinical 
utility of this agent as a new approach to early postthrombo- 
lytic therapy, the effects of ischemia and reperfusion on this 
tracer's kinetics need to be determined. The aim of this study 
was to evaluate the effects of ischemic injury and partial 
necrosis on the kinetics of Tc-99m teboroxime in an isolated 
perfused rat heart model. This model is well suited for 
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Table 1. Mean Technetium-99m Teboroxime Uptake and Proportional Clearance Curves 
Postintervention No-Flow Period 
Group Flow (min) Slope k~on o (l/s) k 1 (l/s) k e (l/s) 
1 Control - -  3.0 -+ 0.7 2.0 _+ 0.3e 4 0.9 _+ 0.5e -3 3.3 + 3.6e -5 
2 Complete reperfusion 30 2.6 -+ 0.8 2.2 +_ 0.4e- 4 1.0 +- 0.2e 3 1.6 -+ 2.7e 5 
3 Complete reperfusion 60 2.1 _+ 0.5* 2.1 +_ 0.2e- 4 1.1 _~ 0.5e- 3 5.8 _+ 5.1e 5_+ 
4 Low flow - -  0.8 -+ 0.2t 0.9 _+ 0.5e -4f 
5 Low flow reperfusion 60 0.8 -+ 0.3f 1.2 _+ 0.3e- 4-~ 
*p = 0.003 versus group 1; tp -< 0.0005 versus groups 1, 2 and 3; :~p = 0,06 versus group 2 (for k2, comparisons made between groups 1, 2 and 3). kmono = 
monoexponential r te constant; k~ - initial clearance rate constant; k2 = second clearance rate constant of bioexponential fit. Level of significance for multiple 
comparisons was p -< 0.005 for slope, 1%1o,  and k I and p -< 0.0125 for k 2 (see Results). 
evaluation of tracer kinetics, in particular clearance kinetics, 
which are critical for understanding this tracer. We evaluated 
reperfusion at both low and normal flow rates to simulate 
incomplete and complete reperfusion after thrombolysis. 
Methods  
The study protocol was approved by the Committee on 
Animal Research at the University of Ottawa and was per- 
formed in accordance with the "Position of the American 
Heart Association on Research Animal Use" adopted by the 
Association in November 1984. The preparation and apparatus 
were similar to those previously described (8). 
Experimental preparation. All hearts were perfused with 
Krebs-Henseleit buffer prepared as follows (mmol/liter): 125.0 
NaC1, 4.7 KC1, 0.4 NaH2PQ, 1.0 MgC12, 1.35 CaC12, 10.0 
D-glucose and 25.0 NaHCO 3. This was continuously bubbled 
with 95% oxygen and 5% carbon dioxide. To study tracer 
kinetics, radiopharmaceutical buffer was prepared by adding 
1.85 MBq/liter of Tc-99m teboroxime to 1 liter of buffer. 
Technetium-99m teboroxime was supplied by Squibb Diagnos- 
tics and prepared according to the product monograph. 
Isolated perfused rat heart preparation. Male Sprague- 
Dawley rats weighing 452 _+ 59 g (obtained from Charles River 
Laboratories, Montreal, Canada) were anesthetized with intra- 
peritoneal sodium pentobarbital (65 mg/kg body weight), 
heparinized and bled through the inferior vena cava isolated 
from an abdominal incision. The thoracic avity was opened 
and the heart was quickly arrested with crushed ice and cold 
saline. The aorta was cannulated atthe level of the innominate 
artery. The heart was removed from the body and mounted on 
a Langendorff perfusion apparatus. The heart was perfused at 
a constant flow rate using a digital roller pump (Piper Pump 
PS11T, Fred A. Dungey Inc., Agincourt, Ontario, Canada). A
constant temperature was maintained at 37°C using a coil- 
condenser heat exchanger connected to a water bath 
(HAAKE). A Latex balloon attached to a pressure transducer 
was inserted through the mitral valve into the left ventricle and 
gradually distended with saline to attain maximal developed 
pressure. The left ventricular pressure was recorded on a 
physiologic chart recorder. The hearts were considered accept- 
able if left ventricular end-diastolic pressure was between 0
and 12 mm Hg, systolic pressure was ->70 mm Hg and 
developed pressure (systolic - diastolic) was >-65 mm Hg 
before initiation of the experiments. Seven hearts did not meet 
these criteria and were excluded from the protocol and anal- 
ysis, leaving 57 hearts: 44 for the radiotracer studies, 11 for 
tissue creatine kinase (CK) analysis and two for histologic 
examination. 
Tracer kinetic monitoring. Myocardial Tc-99m teboroxime 
activity was measured every 2.5 s during the uptake and 
clearance phases using a collimated NaI probe (Canberra 
Nuclear) placed 3 cm from the left ventricle. The output was 
interfaced with a multichannel analyzer (AccuSpec, Canberra 
Nuclear). Activity centered on the 140-keV energy peak was 
displayed using AccuSpec software. Data were then trans- 
ferred to an IBM personal computer for storage and analysis. 
Experimental protocol. All hearts were initially perfused 
with Krebs-Henseleit buffer at 12 ml/min for 15 rain as a 
stabilization phase. The hearts were subsequently divided into 
five groups depending on the duration of complete flow 
interruption (0, 30 or 60 rain) and the level of reperfusion 
flow (low or normal) (Table 1). Group 1 (n = 8, control) = flow 
maintained at 12 ml/min without interruption. This control 
flow rate is in keeping with standard normal buffer perfused 
rat heart experiments (8-11). Group 2 (n = 7) = no flow for 
30 rain, followed by complete reperfusion at 12 ml/min. 
Group 3 (n = 12) = no flow for 60 rain to induce partial 
necrosis, followed by complete reperfusion at 12 ml/min. 
Group 4 (n -- 8) -- continuous low flow rate at 4.5 +_ 0.7 ml/min 
(-40% of baseline) during the experiment without interrup- 
tion of flow. Group 5 (n = 9) = no flow for 60 min, followed by 
low flow reperfusion at 4.8 +_ 0.8 ml/min (-40% of baseline 
flow rate). 
After stabilization i  group 1, 10 rain after the ischemic flow 
rates in group 4 and 10 rain after the onset of reperfusion i
groups 2, 3 and 5, the hearts were perfused for 15 min with 
Krebs-Henseleit buffer containing - 1.85 MBq/liter of Tc-99m 
teboroxime to study tracer uptake. This was followed by 
perfusion with Krebs-Henseleit buffer without Tc-99m 
teboroxime for 35 min as the tracer clearance phase. 
Assessment of cellular injury. Left ventricular tissue CK 
values were measured in an additional set of experiments o 
determine the extent of necrosis induced by 60 min of no flow. 
Six additional control hearts (group 1) and seven additional 
hearts with 60 rain of no flow (group 3) were studied with the 
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same protocol described previously without radiotracer. In five 
control and six no flow/reperfusion experiments, the left 
ventricle was separated from the right ventricle and atrial 
tissue was then divided along its long axis and frozen to -70°C. 
The left ventricular tissue was weighed and then used for tissue 
CK analysis using a standard approach previously described 
(12,13). In one of the additional control and one of the 
additional group 3 experiments, the heart was sliced and 
placed in 10% neutral buffered formalin for histologic analysis. 
The presence of irreversible cellular injury was also evalu- 
ated in groups 1, 3, 4 and 5 by CK release in the effluent, as 
described previously (8). The mean of two samples of effluent 
collected over 5 min during the stabilization phase and then 5 
to 10 min after the intervention was determined. The net 
change in CK release between preintervention a d postinter- 
vention was used as an indicator of the presence of necrosis. 
Tissue preparation for histologic analysis. A section of the 
myocardium was taken at the midventricular level in the short 
axis plane. The section demonstrated both ventricles, including 
the anterolateral nd posteromedial papillary muscles. The 
sections were fixed in 10% neutral buffered formalin and 
embedded inparaffin. The tissue was sectioned at 5-/zm levels 
and stained with hematoxylin phyloxine saffron for evaluation 
of the nuclear changes and cellular esponse, and phospho- 
tungstic acid hematoxylin for the detection of myocardial 
contraction bands. 
Effluent flow rate. The effluent flow rate was measured 
after the intervention in each experiment to confirm the 
desired flow rate. In the 11 additional experiments used for 
tissue CK analysis, the effluent flow rate was measured at 
multiple intervals to confirm the stability of flow in this model. 
These measurements were not performed uring the tracer 
kinetic monitoring experiments because they may interfere 
with the accurate detection of activity in the field of view by the 
probe. 
Data analysis. High resolution time-activity data were sub- 
tracted for background and corrected for physical decay of 
Tc-99m. The uptake phase curves were fit by a linear function 
and the slope was determined. Each clearance phase curve was 
fit by monoexponential and biexponential functions using 
Sigma Plot (Jandel Corp.). Both of these approaches have 
been previously applied to Tc-99m teboroxime clearance data 
(5,14,15). Numerical constants (krno~o for monoexponential 
and k 1 and k 2 for biexponential c earance rates) were deter- 
mined for each curve. The monoexponential and biexponential 
curve fits were compared by assessing the reduction in mean 
squared error using the F statistic. The mean slope (m), the 
clearance rate constants (kmono, k I and k2) and the mean net 
CK release were compared among the experimental groups by 
analysis of variance followed by the unpaired Student t test as 
appropriate. Because of the multiple comparisons, the p values 
for statistical significance were adjusted using the Bonferroni 
correction as appropriate. For comparisons of 3, 4 or five 
groups, p -< 0.0125, p < 0.009 and p -< 0.005, respectively, were 
considered significant. Developed pressure data after the 
intervention were compared to baseline data by the paired 
Student t test (p < 0.05 was considered significant). Results are 
expressed as mean value _+ SD. 
Resul ts  
Hemodynamic recordings. The developed pressure (systol- 
ic - diastolic pressure) was comparable between the groups at 
baseline (means for groups 1, 2, 3, 4 and 5 were 86 + 16, 87 _+ 
15, 90 _+ 17, 85 + 12 and 91 + 13 mm Hg). After the 
intervention, developed pressure fell significantly in all groups 
but the control group (means for group 1 were 90 _+ 22 mm Hg 
[p = NS vs. baseline]; group 2:42 _+ 35 mm Hg; group 3:38 _+ 
34 mm Hg; group 4:54 _+ 20 mm Hg; group 5:48 + 18 mm Hg 
[p < 0.05 vs. baseline for groups 2 to 5]). 
Assessment of cellular injury. Left ventricular tissue CK 
values were significantly reduced by -20% in the group with 
60 min of no flow in comparison to control groups (549 _+ 
75 U/g vs. 696 + 52 U/g, p = 0.005). This significant loss of CK 
indicates the presence of necrosis after 60 min of flow inter- 
ruption. 
Both groups with 60 rain of flow interruption (groups 3 and 
5) had marked change in CK release in the effluent (211 _+ 109 
and 155 _+ 112 U/liter, respectively) incomparison togroups 1 
(control) and 4 (low flow with no flow interruption) (6 _+ 
7 U/liter, p < 0.002 vs. group 3; -4 + 19 U/liter, p < 0.006 vs. 
group 5). This also indicates that 60 rain of no flow induced 
significant myocardial necrosis, although low flow perfusion 
without flow interruption did not. 
Myocardial histologic analysis. On histologic analysis, in 
the additional control heart we identified only rare foci of 
contraction band necrosis (Fig. 1C). These areas were best 
appreciated on phosphotungstic a id hematoxylin stain and 
represented <10% of the area of the myocardium seen in the 
section. No myocytolysis or coagulative necrosis was seen. 
There was no evidence of reperfusion hemorrhage. 
In contrast, he heart from the additional group 3 experi- 
ment (60 rain of no flow with complete reperfusion) had 
marked areas of contraction band necrosis throughout both 
ventricles (Fig. 1A, B). The areas were easily identified on 
phosphotungstic a id hematoxylin stain and were located 
throughout the entire wall thickness (i.e., were not exclusively 
subendocardial). As expected, the areas of contraction band 
necrosis were not associated with neutrophilic nflammation r
coagulative necrosis. No reperfusion hemorrhage was identi- 
fied. 
Tracer kinetic monitoring. Figure 2 shows individual ex- 
amples of Tc-99m teboroxime uptake. The uptake slopes 
appear to be comparable for all groups with normal flow or 
normal reperfusion flow rates (groups 1, 2 and 3). The uptake 
slopes for groups 4 and 5 (low flow and reperfusion low flow) 
are comparable but reduced compared with the other groups. 
In Figure 3, the clearance curve examples how a similar 
pattern for groups 1, 2 and 3. Groups 4 and 5 are also 
comparable, but the clearance rate is reduced compared with 
groups 1, 2 and 3. 
Curves reconstructed from the mean uptake slope for each 
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Figure 1. A, High power photomicrograph of the heart with no flow 
for 60 rain, followed by reperfusion. Multiple areas of contraction 
band necrosis are present. There is myofibril condensation into the 
bands in the myocyte. There is no neutrophilic response. Hema- 
toxylin phloxine saffron x400, reduced by 49%. B, Low power 
photomicrograph of the heart with no flow for 60 rain and subse- 
quent reperfusion. Phosphotungstic a id hematoxylin stain allows 
detection of widespread contraction bands. The inset shows a 
typical contraction band. Phosphotungstic a id hematoxylin x40, 
reduced by 49%. C, Low power photomicrograph of the control 
animal's heart at the same magnification as B for comparison. There 
are almost no contraction bands. Phosphotungstic acid hematoxylin 
×40, reduced by 49%. 
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Figure 2. Examples of technetium-99m teboroxime time-activity up- 
take data. The control and the two examples with complete r perfu- 
sion have similar uptake rates, which were much greater than the 
uptake rates for the low flow and the low flow reperfusion examples. 
group are shown in Figure 4. Mean uptake slope data are 
shown in Table 1. The groups with low flow rates (groups 4and 
5) had reduced uptake slopes (0.8 +_ 0.2 and 0.8 -+ 0.3) in 
comparison to those with normal flow rates or normal reper- 
fusion flow rates (groups 1, 2 and 3:3.0 _+ 0.7, 2.6 +_ 0.8 and 
2.1 +_ 0.5; p _< 0.0005 vs. groups 4 and 5). In groups with 
normal reperfusion flow rates, there was a less prominent but 
significant reduction in slope in group 3 (60 rain of no flow) 
(p = 0.003). 
Table 2 shows the mean proportional activity for the 
clearance phase for l-rain intervals every 5 rain, proportional 
to the mean actMty in the first minute. Table 1 shows the mean 
monoexponential and biexponential c earance functions for 
each group. These two fitting approaches have been used by 
other investigators (5,14,15). Analysis of representative curves 
from each of the five groups showed that the bicxponential 
function improved the fit over the monoexponential function 
in the groups with normal perfusion and reperfusion flow rates 
(groups 1 to 3; p < 0.001), but not in those with reduced flow 
rates (groups 4 and 5). In groups 4 and 5, curves were 
monoexponential; therefore, ka is assumed to be 0, and k 1 
approaches kmono. As such, the biexponential rate constants 
are not reported for these groups. The mean monoexponential 
functions are reported for all groups in Table 1 to facilitate 
group comparisons. 
The groups with reduced flow rates (groups 4 and 5), 
regardless of the duration of no flow, had markedly reduced 
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Figure 3. Examples of technetium-99m teboroxime time-activity pro- 
portional clearance data. The peak activity is assigned avalue of 1.0. 
The control and two complete reperfusion examples have similar 
clearance curves, and the low flow and low flow reperfusion examples 
have slower clearance rates. Greater scatter in the low flow curves 
reflects the lower maximal activity achieved in these two groups (see 
Fig. 1). 
3 with normal flow rates, regardless of the durations of 
preceding no flow, the monoexponential function was similar 
for the three groups (p -- NS). With biexponential fitting, the 
k 1 rate constant was also similar for these three groups (p = 
NS). 
Given the initial clearance rate constant (kl) data, inter- 
group comparisons for k 2 data were made between groups 1, 2 
and 3. Although a trend for higher k 2 values in group 3 was 
observed, there were no statistically significant differences for 
these k 2 comparisons. (With four comparisons, p <- 0.0125 was 
considered significant [Table 1].) As noted above, the clear- 
ance curves for groups 4 and 5 were monoexponential; there- 
fore, k 2 comparisons were not made for these low flow groups. 
Eff luent f low rate. The effluent flow measurements were 
made in the 11 additional experiments at the following time 
points: 1) stabilization, 2) end of uptake phase, 3) at 15 min of 
clearance, and 4) end (last 5 rain) of clearance phase. The 
control group flow rates were 12.2 _+ 0.3, 12.1 _+ 0.3, 12.1 +_ 0.2 
and 11.7 _+ 0.3 ml/min (p = NS). Among the group with 60 rain 
of no flow, the effluent flow rates were 12.5 +_ 0.4, 12.4 _+ 0.4, 
11.9 + 0.8 and 10.4 _+ 1.5 ml/min. In this group the effluent 
flow rate at the end of the clearance phase was slightly reduced 
compared with the other times during the experiment (p = 
0.01 vs. stabilization; p = 0.02 vs. end of uptake and 15 min of 
clearance; for multiple comparisons, p -< 0.005 was considered 
statistically significant). These data indicate that effluent flow 
rates were reasonably stable in this experimental model, except 
for a mild reduction at the end of the clearance phase in the 
group that had 60 min of flow interruption. 
Tc-99m teboroxime initial clearance rates in comparison to the 
groups with normal flow or reperfusion flow (groups 1, 2 and 
3). This was determined using both a monoexponential fit and 
a biexponential fit (kl) (p <-- 0.005 for groups 4 and 5 vs. groups 
1, 2 and 3; p = NS for group 4 vs. group 5). For groups 1, 2 and 
Discussion 
Pr inc ipa l  f indings.  The data from this study show that the 
uptake of Tc-99m teboroxime is significantly reduced in the 
presence of reduced flow. At normal flow rates, the uptake rate 
Figure 4. Mean technetium-99m 
teboroxime uptake and propor- aooo 
tional clearance curves. Groups 4 
and 5 were monoexponential; 25oo 
therefore, the mean monoexpo- 
nential curve is displayed for both A 2000 
clearance graphs. See Table 1 for g. 
statistical comparisons. Solid line = :>, 1500 
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Table 2. Mean Proportional Activity in Clearance Phase 
Time (rain) 
Group* 0-1 5-6 10-11 15-16 20-21 25-26 30-31 34-35]" 
1 1 0.92 ± 0.02 0.84 ± 0.03 0.80 +- 0.03 0.76 -+ 0.03 0.73 +- 0.03 0.69 -+ 0.03 0.67 --- 0.04 
2 1 0.92 -- 0.02 0.84 + 0.03 0.77 ± 0.05 0,73 +- 0.04 0.70 ± 0.04 0.67 -+ 0.04 0.66 + 0.04 
3 1 0.92 -+ 0.02 0.82 ± 0.04 0.78 -+ 0.02 0,74 ± 0.02 0.70 +- 0.02 0.67 -+ 0.02 0.65 + 0.02 
4 1 0.97 ± 0.03 0.96 _+ 0.04 0.94 -+ 0.06 0,91 ± 0.06 0.89 ± 0.07 0.87 +- 0.09 0.81 + 0.05 
5 1 0.98 -+ 0.02 0.94 ± 0.04 0.91 -- 0.04 0.88 ± 0.05 0.85 -- 0.04 0.82 ± 0.04 0.80 ± 0.04 
*See Table 1 for statistical comparison of mean clearance rate constants, t in  two hearts in group 1 and in three hearts in group 4, clearance data were not recorded 
34 min after the peak activity. 
is partially altered by the presence of necrosis and postischemic 
injury. At low flow rates, this difference is not apparent. 
The initial clearance kinetics of Tc-99m teboroxime are also 
altered by changes in flow rather than the presence of necrosis 
and postisehemic injury induced by 60 min of no flow. This is 
reflected in differences in kmono and initial (kl) clearance 
phase. The dependence ofTc-99m teboroxime kinetics on flow 
may permit the use of this tracer to define the success of 
thrombolytic therapy early in the course of myocardial infarc- 
tion. 
Technetium-99m teboroxime as a flow tracer. Technetium- 
99m teboroxime is a neutral ipophilic baronic acid adduct of 
technetium dioxime (BATO) that demonstrates a high level of 
myocardial tissue extraction (5-7,16). Its early retention and 
myocardial clearance rate in canine models correlate with 
blood flow over a wide flow range (5-7,17). Johnson et al. (18) 
also demonstrated reduced Tc-99m teboroxime myocardial 
clearance rates in ischemic zones of myocardium in compari- 
son to nonischemic zones. Clinical studies have also demon- 
strated arapid myocardial washout (19,20), which is delayed in 
zones of ischemia leading to rapid disappearance of exercise 
defects (20). Our study supports these observations. Low flow 
led to significant reductions in both the uptake and initial 
clearance rate of Tc-99m teboroxime. However, unlike the 
current study, these previous investigations did not evaluate 
the effects of postischemic injury and partial necrosis, which is 
relevant in the early course of myocardial infarction and 
reperfusion. 
Technetium-99m teboroxime in myocardial infarction and 
necrosis. For a myocardial perfusion tracer to be useful in 
detecting reperfusion early in the course of acute myocardial 
infarction, a phase of its kinetics needs to depend mainly on 
myocardial blood flow and needs to be independent or only 
minimally dependent on cell viability. In preliminary work, 
Stone et al. (14) used a model of toxin-induced cell injury 
without reduction in flow (8) to show that Tc-99m teboroxime 
clearance was not significantly altered even when there was 
toxin-induced tissue injury. Their conclusion was that Tc-99m 
teboroxime clearance depended mainly on myocardial blood 
flow and was independent of myocardial cell viability. 
In a preliminary report of myocardial infarction with reper- 
fusion in rabbits, Villegas et al. (21) demonstrated a good 
correlation between Tc-99m teboroxime activity and repeffu- 
sion blood flow in the infarct zone 2 h after the onset of 
reperfusion. Technetium-99m "teboroxime distribution was 
essentially equal to the flow at the time of its injection" with or 
without reperfusion (21). These investigators also evaluated 
Tc-99m teboroxime uptake in a pig model of occlusion and 
reperfusion. Sequential imaging of Tc-99m teboroxime could 
distinguish occlusion from complete reperfusion (22). 
In preliminary canine studies of occlusion and reperfusion, 
Chang et al. (15) also demonstrated a correlation between 
Tc-99m teboroxime activity and myocardial blood flow in the 
infarct zone. However, 8 to 12 mix after injection Tc-99m 
teboroxime activity tended to underestimate r perfusion flow 
in comparison to normal zones. Abraham et al. (23) demon- 
strated similar findings at 5 to 7 mix after injection. Previous 
data (6) have shown that the greatest correlation with flow is 
achieved earlier after injection (1 to 2 mix). Indeed, the late 
phase of Tc-99m teboroxime kinetics may depend more on 
viability than its early phase, as discussed later. Rapid sequen- 
tial imaging may be required to evaluate the early clearance 
kinetics in the clinical setting. 
Preceding studies and preliminary reports are consistent 
with our study's findings. In comparison to the controls, 30 mix 
of no flow followed by reperfusion did not alter tracer uptake 
or clearance. After 60 mix of no flow to induce partial necrosis 
but with complete reperfusion, there was a modest but statis- 
tically significant reduction in the uptake slope. The monoex- 
ponential clearance rate constant, however, was not signifi- 
cantly different for the groups with comparable reperfusion 
flow rates. With biexponential nalysis, k I was also similar for 
groups with similar reperfusion flow rates. The kl variable in 
groups 1 to 3 and kmono in low flow groups 4 and 5 reflect he 
early washout from the tissue and is most dependent on flow. 
The k2 variable, in contrast, reflects a slower late phase of 
tissue washout. In the current study there was a trend for the 
group with 60 min of no flow and complete reperfusion (group 
3) to have higher k 2 values (Table 1). However, there was 
considerable variability in the k2 data, in part owing to low 
count statistics toward the end of the clearance phase. In 
addition, the monoexponential function better characterized 
the fit for the low flow groups (groups 4 and 5). Thus, the k 2 
data must be interpreted with caution. To a lesser degree, the 
mild reduction in flow at the end of the clearance phase in the 
groups with necrosis may have also influenced the k 2 data. This 
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late reduction in flow would not be expected to affect k 1, which 
depends predominantly on the early clearance data. However, 
it may have led to a slight underestimation f k 2 in the 60-min 
no flow groups. Definitive conclusions cannot be made from 
the current data regarding the effect of viability on the late 
phase of Tc-99m teboroxime kinetics. Nonetheless, the trend 
observed isconsistent with the preliminary data from Chang et 
al. (15) and the recent data by Abraham et al. (23), who 
sampled tissue data at 8 to 12 rain and 5 to 7 min, respectively, 
after injection. This timing may be relatively late for the 
assessment of myocardial blood flow using this tracer, consid- 
ering its rapid washout kinetics. 
The reduction in uptake in group 3 (60-min no flow/ 
complete reperfusion) may reflect impairment of a slower 
uptake process associated with the late clearance phase of 
teboroxime's kinetics. This slower uptake and clearance pro- 
cess may depend more on cellular integrity than on the rapid 
clearance phase. As such, uptake could be modestly reduced 
while initial clearance remains rapid and mainly flow depen- 
dent (as in the current study). At low flow rates, the major 
factor limiting both phases would be tracer delivery (flow). 
With low flow, the slower uptake and clearance could be so 
delayed that postischemic injury and partial necrosis have little 
detectable effect on kinetics. The clearance becomes monoex- 
ponential. Evaluation of this hypothesis would require serial 
measurements of tracer activity in subcellular components 
(e.g., membrane, cytosol and mitochondria) with and without 
injury at different flow rates. This was not part of the current 
study. 
The previous studies and reports described earlier used 
complete reperfusion and did not compare reperfused versus 
ischemic myocardium. Clinically, myocardial infarction repre- 
sents a mixture of necrotic, ischemic and postischemic tissue 
often with residual stenosis and incomplete reperfusion (2). As 
such, the findings in the low flow group and low flow reperfu- 
sion group in the current study are important. These groups 
demonstrate significant reductions in uptake slope and 
changes in clearance kinetics. In this low flow range, the uptake 
and initial clearance kinetics were not significantly altered after 
60 rain of flow interruption in this model. These data support 
the hypothesis that Tc-99m teboroxime initial clearance kinet- 
ics depend principally on myocardial blood flow. 
Clinical implications. A rapid noninvasive method is re- 
quired to distinguish absent or severely reduced flow from 
normal or mildly reduced flow to the postischemic and in- 
farcted myocardium. This important distinction could be ad- 
dressed by a myocardial perfusion agent whose initial clear- 
ance depends more on myocardial blood flow and less on 
myocardial viability. Data from the current study support hat 
Tc-99m teboroxime is such an agent when evaluated early after 
injection. However, extrapolation of the current study to 
clinical application must be considered with caution. The 
current study uses an animal model, isolated heart tissue and 
buffer perfusate, which may not reflect complex patient sce- 
narios. 
In a recent study by Heller et al. (24), rapid sequential 
teboroxime imaging was performed uring and after balloon 
occlusion for angioplasty. Teboroxime scans distinguished 
acute coronary occlusion from reperfusion and accurately 
identified the occluded artery 93% of the time. These investi- 
gators did not evaluate the effect of reperfusion i the presence 
of necrosis, as was done in the current study. However, the 
results of the study by Heller et al. and those of the current 
study set the stage for large-scale clinical trials to investigate 
the utility of rapid sequential imaging of Tc-99m teboroxime or 
related BATO compounds to identify vessel patency early in 
the course of acute myocardial infarction. 
Technical considerations and limitations. The uptake 
phase in this model represents racer accumulation, which is a 
reflection of both ongoing tracer uptake and tissue clearance. 
The input of tracer is continuous during this phase. This is in 
contrast to bolus injection used in most clinical imaging 
protocols. The latter approach has a higher initial uptake 
followed by a predominant washout phase. Although the 
uptake phase data add to our understanding of this tracer, they 
are not strictly comparable to the uptake kinetics of a bolus 
injection. However, in this rat heart model, the clearance phase 
represents only clearance and is equivalent to washout kinetics 
of a tracer that rapidly becomes unavailable to the myocardium 
either after continuous uptake phase or after a bolus injection. 
Although most radiotracers have some circulating blood activ- 
ity that can continue to be interchanged with tissue, Tc-99m 
teboroxime is unique in that soon after injection much of the 
tracer becomes unavailable to the myocardium because of its 
metabolism and red blood cell binding (25,26). As such, this 
model is well suited for evaluation of the clearance kinetics of 
this tracer. 
In the current study, a flow interruption of 1 h was used. 
This duration is sufficient o induce partial myocardial necrosis 
based on the model of Reimer and Jennings (27). The con- 
traction band necrosis observed in the current study is also 
known as selective cell necrosis or coagulative myocytolysis. 
Neutrophils do not play a role; the primary cellular esponse is
histiocytic. It may be seen within 1 h of flow interruption (as in 
the current study) and may last until macrophages remove the 
myocytes by phagocytosis. The contraction bands are due to an 
influx of calcium causing hypercontraction a d probable ag- 
glutination of myofibril proteins. The myofibers with hypercon- 
tracted myofibrils are eventually phagocytosed by macro- 
phages, leaving empty sarcoplasmic tubes and eventually 
fibrosis (28,29). 
Conclusions. The uptake and initial clearance kinetics of 
Tc-99m teboroxime depend on myocardial blood flow. At 
normal flow rates, partial necrosis and postischemic injury lead 
to a modest reduction in uptake but have no significant effect 
on the initial clearance rate. Uptake and initial clearance 
(kmono and kl) are significantly reduced when flow is reduced. 
However, this reduction is independent of the presence or 
absence of partial necrosis and postischemic injury. Evaluation 
of the Tc-99m teboroxime kinetics or related BATO com- 
pounds may permit noninvasive detection of inadequate coro- 
nary reperfusion early in acute myocardial infarction, as well as 
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identification of patients requiring subsequent revasculariza- 
tion. 
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